Company / Financials
Elicio Therapeutics, Inc. Financials
FY2021-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$28.3M
FY2022 · +883.1% YoY
Net Income
-$54.6M
FY2022 · +31.9% YoY
Profit Margin
-192.8%
FY2022 · net income / revenue
ROE
-67.0%
FY2022 · return on equity
Total Assets
$52.8M
FY2022
Total Debt
-
FY2022
Equity
$81.5M
FY2022
ROA
-103.4%
FY2022 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.36 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$28.3M+883.1% YoYNet Income HistoryProfit after all expenses and taxes-$54.6M+31.9% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$433.0K-63.6% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$39.3M+28.9% YoYSG&A Expense HistorySelling, general, and administrative expenses$18.5M+2.8% YoYR&D Expense HistoryResearch and development spending$48.7M+24.9% YoYInterest Expense HistoryCost of borrowing and debt obligations-$1.8M+79.1% YoYIncome Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-$1.93+64.5% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$1.93+64.5% YoY